Cardiovascular adverse events with cdk4/6 inhibitors:a meta-analysis of randomized controlled trials

Back

Delegates Premium Access

Cardiovascular adverse events with cdk4/6 inhibitors:a meta-analysis of randomized controlled trials

Session: Risk stratification for cancer therapy-related cardiovascular disease

Topic: Diagnosis and Management of Cardiovascular Disease in Patients with Cancer

Speaker: Doctor C. Dolladille (Caen, FR)

Event: ESC Cardio-Oncology 2025

Congress Presentation

Add to my library

About the speaker

Doctor Charles Dolladille

University Hospital of Caen, Caen (France)

0 follower

5 more presentations in this session

Non-uniform cardiovascular risks of tyrosine kinase inhibitors associated with inhibition of C-terminal Src kinase

Speaker: Assistant Professor Y. Chan (Hong Kong, HK)

The emerging role of left atrial strain in cardiovascular risk stratification for multiple myeloma patients undergoing carfilzomib therapy

Speaker: Doctor A. Colomba (Candiolo, IT)

Machine learning modelling using cardiac magnetic resonance images to predict cancer therapy related cardiac dysfunction with external validation in HER2+ breast cancer patients

Speaker: Professor P. Thavendiranathan (Toronto, CA)

Prospective evaluation of cardiac function following anti-BCMA CAR-T therapy in multiple myeloma

Speaker: Doctor I. Sunayama (Nishinomiya, JP)

Cardiovascular safety of modern radiotherapy techniques in breast cancer

Speaker: Mr J. Saldana Garcia (Madrid, ES)

Access the full session

Risk stratification for cancer therapy-related cardiovascular disease

Speakers: Doctor C. Dolladille, Assistant Professor Y. Chan, Doctor A. Colomba, Professor P. Thavendiranathan, Doctor I. Sunayama...

Access

About the event

ESC Cardio-Oncology 2025

20 June - 21 June 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources